‹ ›
MYP_058611
← PREVIOUS NEXT → BACK
Basic Information
EKL3P
Antimicrobial
Antiviral
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV-2
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor
Standard
40 amino acids
C223H344N48O69S
Standard
Sequence
LDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVKWGSGK
Physicochemical Analysis
4833.46 Da
4.76
-3.23
-3.46
-0.0807
-0.84
0.75
-0.09
14.13
87.75
0.1500
12950.00
12950.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1930.99
-9.40
67.0
67.0
170.0
341.0
7.0
39.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0044948 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
Palm
Bio-Activity Profile
Antimicrobial Anti-SARS-CoV-2
inhibition of cell-cell fusion
0.193±0.021 μM
IC50
PaperA highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases PMID34367893 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34367893/
RECORD: Rec_0086735 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
Palm
Bio-Activity Profile
Antimicrobial Anti-SARS-CoV-2
Virus:SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells
3.987±0.682 μM
IC50
PaperA highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases PMID34367893 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34367893/
RECORD: Rec_0129161 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
Palm
Palm
Bio-Activity Profile
Antiviral Anti-SARS-CoV-2 Fusion inhibition
SARS-CoV-2 | Huh-7 cells
3.987±0.682 μM
IC50
Mammalian: 5.5 h; Yeast: 3 min; E. coli: 2 min
PaperA highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. | Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q. | Acta Pharm Sin B. 2021 Aug 2. | DOI:10.1016/j.apsb.2021.07.026 | PMID:34367893 PMID34367893 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34367893/
RECORD: Rec_0149478 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
Palm
Palm
Bio-Activity Profile
Antiviral Anti-SARS-CoV-2 Fusion inhibition
SARS-CoV-2 | 293T/ACE2 cells
5 μM
IC50
Mammalian: 5.5 h; Yeast: 3 min; E. coli: 2 min
PaperA highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. | Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q. | Acta Pharm Sin B. 2021 Aug 2. | DOI:10.1016/j.apsb.2021.07.026 | PMID:34367893 PMID34367893 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34367893/
RECORD: Rec_0196524 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
Palm
Palm
Bio-Activity Profile
Antiviral Fusion inhibition
inhibition of cell-cell fusion
0.193±0.021 μM
IC50
Mammalian: 5.5 h; Yeast: 3 min; E. coli: 2 min
PaperA highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. | Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q. | Acta Pharm Sin B. 2021 Aug 2. | DOI:10.1016/j.apsb.2021.07.026 | PMID:34367893 PMID34367893 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34367893/
1 2 NEXT LAST
Showing 5 records on this page · Page 1 of 2